BrightGene Bio-Medical Technology Innovation Board was listed

Entecavir tablets are approved by ANDA of the United States

Participation in BrightGeneIndonesia

Incorporation of BrightGene Hong Kong Subsidiary

Three Fenjing products have passed the EU GMP certification

Completed financing of 550 million yuan, and Sequoia and Honghui became shareholders

Completed the financing of 180 million yuan in Round D, and Guotou and Huatai became shareholders

Won the China Patent Award

"Zero defect" passed FDA inspection

Capofengin injection is marketed in Europe

It was officially certified by KFDA of South Korea for the first time

It passed the official certification of Japanese PMDA for the first time

Pass the cGMP certification of the US FDA again

Founder Dr. Yuan Jiandong was selected into the "Thousand Talents Program"

Completed round B financing of 60 million yuan, and Lilly led the investment

The wholly-owned subsidiary Xintai Pharmaceutical was completed

Completed shareholding system transformation and renamed as Borui Biomedical (Suzhou) Co., Ltd

Completed round C financing of 150 million yuan and CICC invested

Xintai Pharmaceutical and Boratexing both passed the domestic new version of GMP certification

Develop an autonomous synthesis process of entecavir

Support the first imitation of Tianqing entecavir

It passed the cGMP certification of the US FDA for the first time

Establish a wholly-owned subsidiary, Xintai Pharmaceutical

Two declared indications for BGM0504 injection were approved for clinical trials

BrightGene Bio-Medical Technology Co., Ltd. was awarded the first prize of Suzhou Excellent Patent Award

BrightGene Bio-Medical Technology Co., Ltd. was listed as "National Enterprise Technology Center"

Pimecrolimus chemical API approved for listing

The new project of high-value patent cultivation in Jiangsu Province was approved

BrightGene Bio-Medical Technology Co., Ltd was listed as one of the top 100 private enterprises in Suzhou in 2022

BrightGene Bio-Medical Technology Co., Ltd was included in the fourth batch of Suzhou Self owned Brand Large Enterprises and Leading Enterprises Advanced Technology Research Institute

Agatroban injection  approved for listing

Oseltamivir phosphate dry suspension  approved for listing

2022 Top 100 Private Enterprises in Jiangsu

The foundation laying ceremony of BrightGene's Taixing new production base was a complete success

The foundation laying ceremony of BrightGene s high-end API production base in Shandong was a complete success

Establishment of Etomex Pharmaceutical Holding Subsidiary

Kapofengin acetate for injection approved for marketing (transferred)

Micafungin sodium for injection   Approved for listing